Dmytro Shymkiv commented on Darnitsa’s plans to enter the South Asia markets

Dmytro Shymkiv

Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, said that the pharmaceutical concern is studying in detail the issue of bringing its products to the markets of South Asia. The company’s management is confident that Darnitsa has a high chance of success in this area of development. These conclusions were made on the basis of a detailed analysis of the state of the pharmaceutical market in the world. According to the top manager of Darnitsa, the crisis caused by the Covid-19 pandemic has inevitably affected the pharmaceutical industry. The recognized world leaders in the production of pharmaceuticals had to face enormous challenges. Firstly, there was a sudden increase in demand for certain drugs, which many pharmaceutical factories were not ready for. Secondly, the rapid development of effective vaccines against coronavirus and, on top of that, the restriction of exports and the complete closure of state borders.

Unlike these manufacturers, Ukrainian companies, in particular “Darnitsa”, were able not only to meet the growing demand for medicines locally, but also to enter the European market of medicines. Dmytro Shymkiv said that thanks to the rapid reorientation of the Darnitsa Group’s strategy Ukrainians did not feel a shortage of drugs. At the same time, the pharmaceutical concern was able to export its products to the EU countries in sufficient volume. To consolidate this result, the leadership of “Darnitsa” decided to raise an issue of amending the Association Agreement with the EU. These amendments relate to the mutual recognition of GMP certificates. Shymkiv believes that strengthening interaction with European partners will open up new opportunities for the Ukrainian pharmaceutical industry in the markets of the EU countries.

Assessing the chances of entering the Asian market, Dmytro Shymkiv noted that now the leaders there are the pharmaceutical companies from India and China. They are being protected by the state, which certainly complicates the competition. But the top manager of Darnitsa Group is sure that the Ukrainian manufacturer has something of interest to the Asian consumer. In support of these words, Shymkiv named 10 pharmaceutical brands that Darnitsa launched last year and is already successfully exporting to Europe. All of them meet high international safety and efficacy standards, therefore they are quite capable of competing with Indian and Chinese medicines.